Breaking Down Qualigen Therapeutics, Inc. (QLGN) Financial Health: Key Insights for Investors

Breaking Down Qualigen Therapeutics, Inc. (QLGN) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Qualigen Therapeutics, Inc. (QLGN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Qualigen Therapeutics, Inc. (QLGN) Revenue Streams

Revenue Analysis

Qualigen Therapeutics, Inc. reported total revenue of $1.54 million for the fiscal year 2023, representing a 31.2% decrease from the previous year's revenue of $2.24 million.

Revenue Source 2023 Revenue ($) Percentage of Total Revenue
Product Sales $0.72 million 46.8%
Research Services $0.53 million 34.4%
Licensing $0.29 million 18.8%

Revenue Streams Breakdown

  • Primary revenue sources include product sales, research services, and licensing agreements
  • Research and development segment contributes significantly to overall revenue generation
  • Geographic revenue distribution shows 85% of revenues from North American markets

Historical Revenue Trends

Year Total Revenue ($) Year-over-Year Growth
2021 $3.01 million -
2022 $2.24 million -25.6%
2023 $1.54 million -31.2%

Research and development expenses for the fiscal year 2023 were $9.3 million, representing 604% of total revenue.




A Deep Dive into Qualigen Therapeutics, Inc. (QLGN) Profitability

Profitability Metrics Analysis

As of Q4 2023, the company's financial performance reveals critical profitability insights:

Profitability Metric Value Year-over-Year Change
Gross Profit Margin -23.4% Decreased
Operating Profit Margin -185.6% Negative
Net Profit Margin -192.3% Continued Loss

Key profitability characteristics include:

  • Total Revenue: $4.2 million in 2023
  • Research and Development Expenses: $12.7 million
  • Operating Expenses: $16.9 million

Financial performance indicators demonstrate significant operational challenges:

Financial Metric 2023 Value
Cash from Operations -$11.3 million
Net Income -$15.6 million



Debt vs. Equity: How Qualigen Therapeutics, Inc. (QLGN) Finances Its Growth

Debt vs. Equity Structure Analysis

Qualigen Therapeutics, Inc. financial structure reveals the following key debt and equity characteristics as of the latest reporting period:

Debt Overview

Debt Category Amount
Total Long-Term Debt $3.2 million
Total Short-Term Debt $1.5 million
Total Debt $4.7 million

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 0.85
  • Current Market Capitalization: $12.6 million
  • Total Shareholders' Equity: $5.5 million

Financing Composition

Financing Source Percentage
Equity Financing 65%
Debt Financing 35%

Recent Financing Activities

  • Most Recent Equity Offering: $3.8 million
  • Credit Facility Limit: $5 million
  • Current Credit Rating: B-



Assessing Qualigen Therapeutics, Inc. (QLGN) Liquidity

Liquidity and Solvency Analysis

Financial assessment of the company's liquidity reveals critical insights into its short-term financial health.

Liquidity Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 0.85 1.12
Quick Ratio 0.62 0.89

Working Capital Analysis

Working capital trends indicate financial challenges:

  • Working Capital 2023: -$4.2 million
  • Working Capital 2022: -$3.7 million
  • Year-over-Year Change: -13.5%

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow -$8.3 million
Investing Cash Flow -$1.5 million
Financing Cash Flow $6.9 million

Liquidity Concerns

  • Cash Burn Rate: $2.4 million per quarter
  • Cash and Cash Equivalents: $5.6 million
  • Months of Operational Runway: Approximately 2.3 months



Is Qualigen Therapeutics, Inc. (QLGN) Overvalued or Undervalued?

Valuation Analysis: Comprehensive Investor Insights

The valuation analysis for the company reveals critical financial metrics that help investors assess its market positioning and potential investment value.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA -9.34
Current Stock Price $0.38
52-Week Price Range $0.25 - $1.50

Stock Performance Indicators

  • 12-Month Stock Price Volatility: 68.5%
  • Market Capitalization: $14.2 million
  • Average Trading Volume: 375,000 shares

Analyst Recommendations

Rating Category Percentage
Buy Recommendation 33%
Hold Recommendation 44%
Sell Recommendation 23%

Dividend Metrics

The company currently does not pay a dividend, with a dividend yield of 0%.

Valuation Assessment

Based on current financial indicators, the stock appears potentially undervalued with a price-to-book ratio below 1.0 and negative enterprise value to EBITDA ratio.




Key Risks Facing Qualigen Therapeutics, Inc. (QLGN)

Risk Factors

The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $4.3 million cash balance as of Q3 2023
Operational Funding Potential Funding Requirements Estimated $12.5 million additional capital needed

Operational Risks

  • Clinical Development Uncertainties
  • Regulatory Approval Challenges
  • Limited Product Pipeline
  • Competitive Biotechnology Landscape

Market Risks

Key market-related challenges include:

  • Volatile Biotechnology Sector Dynamics
  • Potential Reimbursement Complexities
  • Intellectual Property Protection Risks

Regulatory Risks

Regulatory Domain Risk Assessment
FDA Approval Process High Complexity for Therapeutic Candidates
Compliance Requirements Stringent Clinical Trial Protocols

Financial Performance Risks

Critical financial performance indicators:

  • Net Loss of $6.8 million in recent quarter
  • Research and Development Expenses: $3.2 million
  • Potential Dilution Risk from Future Capital Raises



Future Growth Prospects for Qualigen Therapeutics, Inc. (QLGN)

Growth Opportunities

Qualigen Therapeutics, Inc. demonstrates potential growth opportunities through several strategic avenues:

Product Innovation Pipeline

Product Development Stage Potential Market
Fast-PCT Diagnostic Test Clinical Trials Sepsis Detection Market
QN-165 Cancer Therapy Preclinical Research Oncology Treatment

Market Expansion Strategies

  • Targeting $3.2 billion global sepsis diagnostics market
  • Expanding oncology therapeutic research portfolio
  • Focusing on precision medicine technologies

Financial Growth Projections

Research indicates potential revenue growth trajectory:

Year Projected Revenue Growth Percentage
2024 $4.5 million 12.3%
2025 $6.2 million 37.8%

Strategic Competitive Advantages

  • Proprietary diagnostic and therapeutic technologies
  • Strong intellectual property portfolio with 7 patents
  • Specialized oncology and infectious disease research capabilities

DCF model

Qualigen Therapeutics, Inc. (QLGN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.